Alltrna's ML-driven platform optimizes sequence and modifications from natural tRNAs to significantly increase premature termination codon (PTC) readthrough First Alltrna-engineered tRNA ...

CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve ...

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...

Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...

For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

(A) Suppressor tRNA readthrough strategy. Natural tRNAs with engineered anticodons are charged with canonical amino acids to enable readthrough of the premature termination codon (PTC). (B) Unnatural ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian cells, researchers from Peking University led by Chen Peng from College of ...

When Daniel Fischer cofounded Tevard Biosciences in 2017, he wasn’t trying to bet on the next hot RNA technology. His interest was more personal. His daughter Natasha has Dravet syndrome, a rare form ...

tRNAs have a distinct cloverleaf secondary structure and an L-shaped tertiary structure. The cloverleaf structure is formed by the folding of the single-stranded tRNA molecule, which is typically ...

Alltrna's ML-driven platform has screened billions of tRNA molecules in silico to precisely engineer therapeutic properties driven by tRNA sequence and chemical modifications Alltrna presents data ...